AR007194A1 - Suspensiones acuosas de ésteres de ácido graso de 9-hidroxirrisperidona. - Google Patents

Suspensiones acuosas de ésteres de ácido graso de 9-hidroxirrisperidona.

Info

Publication number
AR007194A1
AR007194A1 ARP970102112A ARP970102112A AR007194A1 AR 007194 A1 AR007194 A1 AR 007194A1 AR P970102112 A ARP970102112 A AR P970102112A AR P970102112 A ARP970102112 A AR P970102112A AR 007194 A1 AR007194 A1 AR 007194A1
Authority
AR
Argentina
Prior art keywords
fatty acid
hydroxyrrisperidone
acid esters
aqueous suspensions
pharmaceutically acceptable
Prior art date
Application number
ARP970102112A
Other languages
English (en)
Spanish (es)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR007194(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR007194A1 publication Critical patent/AR007194A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ARP970102112A 1996-05-20 1997-05-19 Suspensiones acuosas de ésteres de ácido graso de 9-hidroxirrisperidona. AR007194A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20

Publications (1)

Publication Number Publication Date
AR007194A1 true AR007194A1 (es) 1999-10-13

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102112A AR007194A1 (es) 1996-05-20 1997-05-19 Suspensiones acuosas de ésteres de ácido graso de 9-hidroxirrisperidona.

Country Status (37)

Country Link
US (1) US6077843A (enExample)
EP (1) EP0904081B1 (enExample)
JP (1) JP3274687B2 (enExample)
KR (1) KR100358373B1 (enExample)
CN (1) CN1093762C (enExample)
AR (1) AR007194A1 (enExample)
AT (1) ATE208619T1 (enExample)
AU (1) AU715572B2 (enExample)
BG (1) BG62684B1 (enExample)
BR (1) BR9706824B8 (enExample)
CA (1) CA2236691C (enExample)
CY (2) CY2270B1 (enExample)
CZ (1) CZ291284B6 (enExample)
DE (2) DE69708284T2 (enExample)
DK (1) DK0904081T3 (enExample)
EA (1) EA000536B1 (enExample)
EE (1) EE03594B1 (enExample)
ES (1) ES2167745T3 (enExample)
FR (1) FR11C0035I2 (enExample)
HR (1) HRP970276B1 (enExample)
HU (2) HU224025B1 (enExample)
ID (1) ID16927A (enExample)
IL (1) IL124551A (enExample)
LU (1) LU91842I2 (enExample)
MX (1) MX9804816A (enExample)
MY (1) MY126302A (enExample)
NO (2) NO315931B1 (enExample)
NZ (1) NZ330369A (enExample)
PL (1) PL188309B1 (enExample)
PT (1) PT904081E (enExample)
SI (1) SI0904081T1 (enExample)
SK (1) SK284013B6 (enExample)
TR (1) TR199800923T2 (enExample)
TW (1) TW487572B (enExample)
UA (1) UA61898C2 (enExample)
WO (1) WO1997044039A1 (enExample)
ZA (1) ZA974331B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
DE69917000T2 (de) * 1998-02-25 2005-04-21 Abbott Lab Butorphanol enthaltende formulierungen mit verzögerter freisetzung
WO2000010572A1 (en) * 1998-08-18 2000-03-02 Sepracor Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
BR0009437A (pt) 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Amido pré-gelatinizado em uma formulação de liberação controlada
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
CA2419314C (en) * 2000-08-14 2006-07-11 Teva Pharmaceutical Industries Ltd. Preparation of risperidone
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
JP4500679B2 (ja) * 2002-07-29 2010-07-14 アルザ・コーポレーシヨン パリペリドンを制御送達する方法および投薬形態物
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
AU2004285448C1 (en) 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
US8221778B2 (en) * 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CA2553254C (en) * 2004-01-12 2013-12-17 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
US8314110B2 (en) * 2007-04-19 2012-11-20 Youxin Li Compounds for treating mental disorders, and preparation and uses thereof
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
SI2234617T2 (sl) 2007-12-19 2025-05-30 Janssen Pharmaceutica Nv Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje
US20090209757A1 (en) * 2008-01-10 2009-08-20 Santiago Ini Processes for the preparation and purification of paliperidone palmitate
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
SI2341905T2 (sl) 2008-09-04 2024-02-29 Amylin Pharmaceuticals, Llc Formulacije s podaljšanim sproščanjem z uporabo brezvodnih nosilcev
NO2462246T3 (enExample) 2009-09-28 2018-02-03
CA2742393A1 (en) 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
WO2011074017A1 (en) * 2009-12-17 2011-06-23 Alkem Laboratories Ltd. A novel process for the preparation of paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2012053654A1 (en) 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2683717B1 (en) * 2011-05-31 2016-05-25 Ramamohan Rao, Davuluri Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido[ 1, 2-a]-pyrimidin-4-one (paliperidone) and paliperidone palmitate.
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2802299T3 (es) 2015-04-07 2021-01-18 Janssen Pharmaceuticals Inc Régimen de dosificación para dosis olvidadas para ésteres de paliperidona inyectables de acción prolongada
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
TWI754643B (zh) 2016-05-16 2022-02-11 美商因塔希亞治療公司 升糖素受體選擇性多肽和彼之使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
JP2023551007A (ja) 2020-11-30 2023-12-06 ヤンセン ファーマシューティカ エヌ．ベー． パルミチン酸パリペリドン製剤の再懸濁を確実にする方法
DK4025188T3 (da) 2020-11-30 2024-03-04 Janssen Pharmaceutica Nv Doseringsregimer associeret med injicerbare paliperidonformuleringer med forlænget frigivelse
EP4025189B1 (en) 2020-11-30 2024-06-05 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
EP4385564A3 (en) 2020-11-30 2024-10-09 JANSSEN Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CA3229731A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
HU219487B (hu) * 1993-11-19 2001-04-28 Janssen Pharmaceutica Nv. Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
EP0729353B2 (en) * 1993-11-19 2012-09-12 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
WO1996039405A1 (en) * 1995-06-06 1996-12-12 Hoechst Marion Roussel, Inc. Pyridiniminyl-1,2-benzisoxazoles and- benzisothiazoles as antipsychotic agents
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
WO1997044039A1 (en) 1997-11-27
CN1206347A (zh) 1999-01-27
BR9706824B8 (pt) 2015-02-18
AU715572B2 (en) 2000-02-03
HUP9901319A3 (en) 1999-11-29
HUS1100013I1 (hu) 2017-03-28
TW487572B (en) 2002-05-21
ES2167745T3 (es) 2002-05-16
HRP970276A2 (en) 1998-04-30
DK0904081T3 (da) 2002-02-25
ATE208619T1 (de) 2001-11-15
KR100358373B1 (ko) 2003-02-11
NO315931B1 (no) 2003-11-17
SK284013B6 (sk) 2004-08-03
BG62684B1 (bg) 2000-05-31
ZA974331B (en) 1998-11-19
NO2011015I2 (no) 2013-03-11
HU224025B1 (hu) 2005-05-30
CY2270B1 (en) 2003-07-04
FR11C0035I1 (enExample) 2011-07-10
AU2955997A (en) 1997-12-09
EP0904081A1 (en) 1999-03-31
ID16927A (id) 1997-11-20
KR19990067603A (ko) 1999-08-25
EE03594B1 (et) 2002-02-15
SI0904081T1 (en) 2002-04-30
BG102443A (en) 1999-06-30
LU91842I2 (fr) 2011-09-20
EP0904081B1 (en) 2001-11-14
PL327995A1 (en) 1999-01-04
US6077843A (en) 2000-06-20
JP3274687B2 (ja) 2002-04-15
NO981984D0 (no) 1998-04-30
DE69708284T2 (de) 2002-07-25
MX9804816A (es) 1998-10-31
EE9800136A (et) 1998-10-15
MY126302A (en) 2006-09-29
CZ140198A3 (cs) 1999-04-14
UA61898C2 (en) 2003-12-15
DE69708284D1 (de) 2001-12-20
BR9706824A (pt) 1999-03-23
PT904081E (pt) 2002-04-29
JP2000513718A (ja) 2000-10-17
IL124551A0 (en) 1998-12-06
CZ291284B6 (cs) 2003-01-15
SK62098A3 (en) 2000-04-10
TR199800923T2 (xx) 1999-09-21
DE122011100027I1 (de) 2011-11-17
NO981984L (no) 1998-11-19
NZ330369A (en) 2000-04-28
NO2011015I1 (no) 2011-09-19
CA2236691A1 (en) 1997-11-27
EA000536B1 (ru) 1999-10-28
PL188309B1 (pl) 2005-01-31
FR11C0035I2 (fr) 2013-08-16
CA2236691C (en) 2007-01-02
CY2011011I2 (el) 2016-12-14
HRP970276B1 (en) 2002-04-30
CY2011011I1 (el) 2016-12-14
HK1017852A1 (en) 1999-12-03
EA199800531A1 (ru) 1998-12-24
CN1093762C (zh) 2002-11-06
HUP9901319A2 (hu) 1999-08-30
IL124551A (en) 2001-08-26

Similar Documents

Publication Publication Date Title
AR007194A1 (es) Suspensiones acuosas de ésteres de ácido graso de 9-hidroxirrisperidona.
BR9814202A (pt) Supensões aquosas de ésteres submicrÈnicos do ácido graxo 9-hidróxi-risperidona
JPS6431729A (en) Novel use for 5ht-3 antagonist
ES2058109T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica antimicrobiana topica.
UA41502C2 (uk) Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
TR200102170T2 (tr) Psikiyatrik ve nörolojik bozukluklar için yüksek ölçüde saflaştırılmış etil EPA ve diğer EPA türevleri.
SE8503664L (sv) Ett system for tillforsel av lekemedel
ES2074124T3 (es) Composicion en forma de una espuma que contiene acido 5-aminosalicilico para administracion intra-rectal.
UY25225A1 (es) Derivados de pleuromutilina utiles como agentes antimicrobianos
AR031072A1 (es) Composiciones anticonvulsivas y el uso de las mismas para la manufactura de un medicamento
IL97796A0 (en) Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation
ES2052761T3 (es) Nuevos esteres del acido androstano 17-carboxilico, procedimiento para su preparacion y medicamento que los contiene.
ES2021904A6 (es) Procedimiento para preparar una composicion farmaceutica a base de un acido piperacinacarboxilico.
NZ332497A (en) Pharmaceutical composition having a carrier system containing a combination of an alkylene glycol and unsaturated fatty acid alcohol as the solvent and a stiffening agent
AR008243A1 (es) Un derivado de 1-[6-(piridin-3-iloxi)-pirid(az)in-3-ilcarbamoil]indolina, un procedimiento para su preparacion, composicion farmaceutica y su uso para lafabricacion de un medicamento
Tabushi et al. Electroencephalographic study of the effects of methysergide on sleep in the rabbit
CO5271647A1 (es) Metodo para prevenir la diarrea
MX9300057A (es) Ester especial del acido 1,4-dihidropiridin-3,5-dicarboxilico y procedimiento para su obtencion.
ES2031462T3 (es) Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.
FR2387035A1 (fr) Nouveau medicament destine notamment au traitement des troubles fonctionnels cerebraux
US4837203A (en) Pharmacologically active compounds and use
DE69803772D1 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung
ES2033258T3 (es) Procedimiento para preparar una composicion para sistema terapeuticos transdermales.
Decsi et al. Effect of (d-Met2, Pro5) enkephalinamide, a highly potent opiate agonist, on the drinking behaviour of rats

Legal Events

Date Code Title Description
FG Grant, registration